Forma Therapeutics, Inc.

Array Biopharma Inc.

Kymera Therapeutics, Inc.

Duncan Walker

Susan Ashwell

Wei Lu

Alan Collis

Patrick F Kelly

Blythe Thomson

Jeff Davis

Richard D Woessner

Brian J Tunquist

Lu Wei

Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)

The present invention relates to methods of treating MYD88-mutant B-cell lymphomas using IRAK4 degrader.

Methods of treating mutant lymphomas

Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).

Inhibiting mutant IDH-1

Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation

Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.

Method of treatment using inhibitors of mitosis

Growing community of inventors

Boulder, CO, United States of America

Duncan Walker